A policy brief outlines recommendations for G20 members to act together to accelerate TB vaccine development.
TB, which continues to be a global pandemic, is a pressing public health, human rights, and economic concern. At least one new TB vaccine must be licensed and approved by 2025 to meet the World Health Organization’s goal of ending TB by 2030.
The G20 includes many countries with a high burden of TB and is uniquely positioned to lead TB vaccine development and delivery through joint, sustained, and scaled-up investments. A policy brief outlines recommendations for G20 members to act together to accelerate TB vaccine development. An “investment toolbox” is proposed, adaptable to each country’s economic and research capacities and disease burden.
Access the policy brief here.